Andreas K Buck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5481065/publications.pdf

Version: 2024-02-01

229 papers	13,246 citations	17440 63 h-index	27406 106 g-index
241 all docs	241 docs citations	241 times ranked	12750 citing authors

#	Article	IF	Citations
1	⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine, 2022, 63, 96-99.	5.0	13
2	Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging. Clinical Nuclear Medicine, 2022, 47, 651-652.	1.3	6
3	Adrenal functional imaging. Presse Medicale, 2022, 51, 104114.	1.9	3
4	Molecular Imaging in Multiple Myelomaâ€"Novel PET Radiotracers Improve Patient Management and Guide Therapy. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	2
5	Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. Molecular Imaging and Biology, 2022, 24, 659-665.	2.6	17
6	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1348-e1355.	3.6	5
7	Responsivity of the Striatal Dopamine System to Methylphenidateâ€"A Within-Subject I-123-Î²-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Frontiers in Psychiatry, 2022, 13, 804730.	2.6	4
8	Minimal residual disease and imagingâ€guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. British Journal of Haematology, 2022, 198, 515-522.	2.5	7
9	CXCR4-targeted theranostics in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4133-4144.	6.4	48
10	Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. Endocrine, 2022, 78, 169-176.	2.3	5
11	Pasotuxizumab, a BiTE^{Â®} immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy, 2021, 13, 125-141.	2.0	72
12	Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. Journal of Nuclear Medicine, 2021, 62, 1415-1421.	5.0	38
13	CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics, 2021, 11, 605.	2.6	18
14	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Frontiers in Endocrinology, 2021, 12, 643328.	3.5	12
15	Pulmonary vasculitis due to infection with Mycobacterium goodii: A case report. International Journal of Infectious Diseases, 2021, 104, 178-180.	3.3	0
16	Thyroid incidentalomas with increased focal 18F-FDG uptake in 18F-FDG PET/CT of a patient with multiple primary cancers.. Endocrine, 2021, 73, 491-492.	2.3	1
17	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
18	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16

#	Article	IF	Citations
19	Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	6.4	7
20	Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Research, 2021, 11, 77.	2.5	16
21	The Number of Frames on ECG-Gated 18F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters. Molecular Imaging, 2021, 2021, 1-8.	1.4	2
22	Secondary Biphenotypic Acute Leukemia Following Rosai-Dorfman-Disease A Coincidence?. Klinische Padiatrie, 2021, , .	0.6	0
23	Imaging Inflammation in Atherosclerosis with CXCR4-Directed ⁶⁸Ga-Pentixafor PET/CT: Correlation with ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 751-756.	5.0	45
24	¹⁸F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020, 10, 1-16.	10.0	117
25	18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. Cancers, 2020, 12, 2333.	3.7	16
26	The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT. Cancers, 2020, 12, 2399.	3.7	4
27	Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clinical and Translational Radiation Oncology, 2020, 22, 29-32.	1.7	20
28	18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers, 2020, 12, 1042.	3.7	24
29	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1765-1771.	5.0	34
30	Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements. Journal of Neural Transmission, 2020, 127, 851-873.	2.8	18
31	T-Staging and Target Volume Definition by Imaging in GI Tumors. Medical Radiology, 2020, , 203-220.	0.1	0
32	Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma. Blood, 2020, 136, 17-18.	1.4	0
33	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2019, 60, 60-64.	5.0	62
34	CXCR4-Directed Imaging in Solid Tumors. Frontiers in Oncology, 2019, 9, 770.	2.8	47
35	[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. Frontiers in Oncology, 2019, 9, 503.	2.8	15
36	Side Effects of CXC-Chemokine Receptor 4â€“Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. Journal of Nuclear Medicine, 2019, 60, 1399-1405.	5.0	37

#	Article	IF	Citations
37	Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. Molecular Imaging and Biology, 2019, 21, 1174-1181.	2.6	7
38	Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomography. Nuclear Medicine Communications, 2019, 40, 1001-1004.	1.1	5
39	Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma. Clinical Nuclear Medicine, 2019, 44, 620-624.	1.3	30
40	Hexokinase-2 Expression in ¹¹C-Methionineâ€“Positive, ¹⁸F-FDGâ€“Negative Multiple Myeloma. Journal of Nuclear Medicine, 2019, 60, 348-352.	5.0	21
41	Potential influence of concomitant chemotherapy on <scp>CXCR</scp>4 expression in receptor directed endoradiotherapy. British Journal of Haematology, 2019, 184, 440-443.	2.5	25
42	Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With [68Ga]Pentixafor-PET/CT in Correlation WithÂCardiac MRI. JACC: Cardiovascular Imaging, 2018, 11, 1541-1543.	5.3	42
43	Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1694-1704.	6.4	23
44	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
45	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. Journal of Nuclear Medicine, 2018, 59, 1085-1091.	5.0	58
46	[¹¹C]Methionine emerges as a new biomarker for tracking active myeloma lesions. British Journal of Haematology, 2018, 181, 701-703.	2.5	13
47	Predictive Value of ¹⁸F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. Journal of Nuclear Medicine, 2018, 59, 756-761.	5.0	26
48	The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?. Theranostics, 2018, 8, 6088-6100.	10.0	59
49	Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics, 2018, 8, 644-649.	10.0	11
50	Chemokine Receptor 4 Expression in Primary SjÃ¶grenâ€™s Syndrome. Clinical Nuclear Medicine, 2018, 43, 835-836.	1.3	13
51	Anti-Inflammatory Effects on Atherosclerotic Lesions Induced by CXCR4-Directed Endoradiotherapy. Journal of the American College of Cardiology, 2018, 72, 122-123.	2.8	10
52	Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on ⁶⁸Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods. Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	93
53	Gastroesophageal Cancer. , 2018, , 65-84.		0
54	CXCR4-directed theranostics in oncology and inflammation. Annals of Nuclear Medicine, 2018, 32, 503-511.	2.2	98

#	Article	IF	Citations
55	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. Theranostics, 2018, 8, 369-383.	10.0	68
56	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine, 2018, 32, 512-522.	2.2	37
57	18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer. Oncotarget, 2018, 9, 10128-10134.	1.8	8
58	The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1097-1098.	6.4	11
59	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clinical Nuclear Medicine, 2017, 42, e29-e34.	1.3	60
60	Intraindividual tumor heterogeneity in NET â€“ Further insight by C-X-C motif chemokine receptor 4-directed imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 553-554.	6.4	10
61	Chemokine receptor â€“ Directed imaging and therapy. Methods, 2017, 130, 63-71.	3.8	45
62	Cholinergic activity and levodopaâ€induced dyskinesia: a multitracer molecular imaging study. Annals of Clinical and Translational Neurology, 2017, 4, 632-639.	3.7	15
63	[⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values. Theranostics, 2017, 7, 205-212.	10.0	138
64	[¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017, 7, 2350-2362.	10.0	84
65	¹¹C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics, 2017, 7, 2956-2964.	10.0	63
66	Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget, 2017, 8, 7039-7049.	1.8	54
67	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics, 2017, 7, 1589-1597.	10.0	102
68	Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics, 2017, 7, 1489-1498.	10.0	82
69	Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. Oncotarget, 2017, 8, 96732-96737.	1.8	17
70	¹¹C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement. Theranostics, 2016, 6, 254-261.	10.0	80
71	Combined [18F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice. Journal of Neuroinflammation, 2016, 13, 140.	7.2	59
72	⁶⁸Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. Theranostics, 2016, 6, 428-434.	10.0	91

#	Article	IF	Citations
73	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clinical Nuclear Medicine, 2016, 41, 515-521.	1.3	165
74	Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Research, 2016, 6, 78.	2.5	78
75	Peptide Receptor Radionuclide Therapy for Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1428-1430.	5.6	7
76	Assessment of tumor heterogeneity in treatment-naÃ¯ve adrenocortical cancer patients using 18F-FDG positron emission tomography. Endocrine, 2016, 53, 791-800.	2.3	8
77	Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy?. Brain, 2016, 139, 2948-2956.	7.6	119
78	Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2304-2312.	6.4	28
79	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
80	[⁶⁸ Ga]Pentixaforâ€“Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke. Circulation: Cardiovascular Imaging, 2016, 9, e005217.	2.6	15
81	DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. Journal of Nuclear Medicine, 2016, 57, 173-179.	5.0	49
82	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	5.0	201
83	Evidence of impaired carbohydrate assimilation in euthyroid patients with Hashimotoâ€™s thyroiditis. European Journal of Clinical Nutrition, 2016, 70, 222-228.	2.9	3
84	Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. PLoS ONE, 2016, 11, e0160282.	2.5	9
85	[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience. Oncotarget, 2016, 7, 9288-9295.	1.8	92
86	Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget, 2016, 7, 20033-20040.	1.8	41
87	FLT PET/CT-Guided Biopsy in the Evaluation of Cancer. , 2016, , 65-76.		0
88	In vivo molecular imaging of chemokine receptor <scp>CXCR</scp> 4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine, 2015, 7, 477-487.	6.9	180
89	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer, 2015, 15, 1002.	2.6	42
90	Paralytic Subileus as an Adverse Effect of Amino Acidâ€“Based Nephroprotection in a Patient Undergoing Peptide Receptor Radionuclide Therapy. Clinical Nuclear Medicine, 2015, 40, 263-264.	1.3	1

#	Article	IF	Citations
91	11C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget, 2015, 6, 8418-8429.	1.8	38
92	Tumor-Associated Macrophages in Glioblastoma Multiformeâ€"A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?. PLoS ONE, 2015, 10, e0122269.	2.5	31
93	Imaging of myocardial inflammation with somatostatin receptor based PET/CT â€" A comparison to cardiac MRI. International Journal of Cardiology, 2015, 194, 44-49.	1.7	86
94	[68Ga]Pentixafor-PET/CT for Imaging ofÂChemokine Receptor 4 Expression After Myocardial Infarction. JACC: Cardiovascular Imaging, 2015, 8, 1466-1468.	5.3	56
95	Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nuclear Medicine and Biology, 2015, 42, 349-354.	0.6	40
96	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	5.0	108
97	Improved synthesis of [18F]FS-PTAD as a new tyrosine-specific prosthetic group for radiofluorination of biomolecules. Applied Radiation and Isotopes, 2015, 104, 136-142.	1.5	19
98	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	5.0	122
99	iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1692-1699.	6.4	26
100	Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer. International Journal of Oral and Maxillofacial Surgery, 2015, 44, 8-15.	1.5	22
101	Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [¹⁸F]Fluorothymidine-PET. Advances in Molecular Imaging, 2015, 05, 17-28.	0.3	1
102	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of ParkinsonÃ¢â‚¬â„¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 213.	3.4	21
103	Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. OncoTargets and Therapy, 2014, 7, 789.	2.0	11
104	Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Research, 2014, 4, 74.	2.5	9
105	Targeting P-Selectin by Gallium-68â€"Labeled Fucoidan Positron Emission Tomography for Noninvasive Characterization of Vulnerable Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1661-1667.	2.4	58
106	Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy. EJNMMI Research, 2014, 4, 46.	2.5	8
107	Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2222-2231.	6.4	86
108	PET Tracers in Musculoskeletal Disease beyond FDG. Seminars in Musculoskeletal Radiology, 2014, 18, 123-132.	0.7	13

#	Article	IF	Citations
109	Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-Oncology, 2014, 16, 603-609.	1.2	94
110	Intraoperative 3-D imaging improves sentinel lymph node biopsy in oral cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2257-2264.	6.4	44
111	Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy. Nuclear Medicine Communications, 2014, 35, 1143-1149.	1.1	4
112	The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2281-2290.	6.4	32
113	Three-Phase Bone Scintigraphy for Imaging Osteoradionecrosis of the Jaw. Clinical Nuclear Medicine, 2014, 39, 21-25.	1.3	13
114	Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. European Journal of Haematology, 2014, 93, 545-546.	2.2	3
115	Proliferation Imaging with 18F-Fluorothymidine PET/Computed Tomography. PET Clinics, 2014, 9, 331-338.	3.0	11
116	Early development of a celiac trunk aneurysm during anti-vascular endothelial growth factor receptor therapy. Surgery, 2014, 155, 729-730.	1.9	3
117	18ÂF-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair. EJNMMI Research, 2014, 4, 3.	2.5	2
118	The lymphoma-like polychemotherapy regimen â€œDexa-BEAMâ€•in advanced and extramedullary multiple myeloma. Annals of Hematology, 2014, 93, 1207-1214.	1.8	29
119	Diagnostic Findings and Treatment in a 51-Year-Old Woman With Oncogenic Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 385-386.	3.6	2
120	Freehand SPECTâ€guided sentinel lymph node biopsy in early oral squamous cell carcinoma. Head and Neck, 2014, 36, E112-6.	2.0	35
121	NicotinicÎ±4Î²2acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurologica Scandinavica, 2014, 130, 164-171.	2.1	21
122	Small-Animal PET Imaging of Isolated Perfused Rat Heart. Journal of Nuclear Medicine, 2014, 55, 495-499.	5.0	4
123	Comparison of the Amino Acid Tracers ¹⁸F-FET and ¹⁸F-DOPA in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2014, 55, 1611-1616.	5.0	90
124	Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer, 2014, 14, 268.	2.6	51
125	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. Oncotarget, 2014, 5, 4050-4059.	1.8	23
126	18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget, 2014, 5, 7381-7391.	1.8	56

#	Article	IF	Citations
127	PET Imaging with [⁶⁸Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluoroethylcholine. Current Cancer Drug Targets, 2014, 14, 371-379.	1.6	17
128	Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature, 2013, 501, 421-425.	27.8	437
129	¹⁸Fâ€Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer, 2013, 119, 1227-1234.	4.1	44
130	Specific somatostatin receptor II expression in arterial plaque: 68Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis, 2013, 230, 33-39.	0.8	75
131	[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 34-43.	6.4	35
132	Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1508-1518.	3.6	47
133	[123I]Iodometomidate Imaging in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2755-2764.	3.6	45
134	Life Expectancy Is Reduced in Differentiated Thyroid Cancer Patients â‰¥ 45 Years Old with Extensive Local Tumor Invasion, Lateral Lymph Node, or Distant Metastases at Diagnosis and Normal in All Other DTC Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 172-180.	3.6	166
135	Relationship Between Antithyroglobulin Autoantibodies and Thyroglobulin Recovery Rates Using Different Thyroglobulin Concentrations in the Recovery Buffer. Hormone and Metabolic Research, 2013, 45, 728-735.	1.5	12
136	Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?. PLoS ONE, 2013, 8, e71729.	2.5	28
137	Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology. PLoS ONE, 2013, 8, e84840.	2.5	28
138	Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 70-9.	1.0	10
139	[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 914-922.	3.6	70
140	¹⁸F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions. Journal of Nuclear Medicine, 2012, 53, 1269-1276.	5.0	36
141	FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy. Cancer Research, 2012, 72, 5014-5024.	0.9	37
142	68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Research, 2012, 2, 52.	2.5	107
143	Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiation Oncology, 2012, 7, 99.	2.7	71
144	PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1284-1288.	6.4	42

#	Article	IF	Citations
145	Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clinical Endocrinology, 2012, 76, 586-592.	2.4	67
146	Pancreatic and Hepatobiliary Cancers. Methods in Molecular Biology, 2011, 727, 243-264.	0.9	2
147	Influence of 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiotherapy and Oncology, 2011, 99, 193-200.	0.6	101
148	Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Annals of Surgical Oncology, 2011, 18, 3316-3323.	1.5	58
149	PET/CT for staging lung cancer: costly or cost-saving?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 799-801.	6.4	15
150	Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2005-2013.	6.4	47
151	Predictive Value of Initial¹⁸F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. Journal of Nuclear Medicine, 2011, 52, 690-696.	5.0	65
152	Facing the Nuclear Threat: Thyroid Blocking Revisited. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3511-3516.	3.6	31
153	A Pilot Study to Evaluate 3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma. Journal of Nuclear Medicine, 2011, 52, 1898-1902.	5.0	29
154	Functional Imaging of Pheochromocytoma with⁶⁸Ga-DOTATOC and⁶⁸C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia. International Journal of Molecular Imaging, 2011, 2011, 1-9.	1.3	13
155	Melanoma Metastases to Palatine Tonsils Obscured by Physiological FDG Uptake on PET/CT. Clinical Nuclear Medicine, 2010, 35, 101-102.	1.3	2
156	Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 484-493.	6.4	62
157	First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1452-1461.	6.4	155
158	[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1861-1868.	6.4	23
159	Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. Archives of Orthopaedic and Trauma Surgery, 2010, 130, 819-827.	2.4	18
160	PET/CT with ¹⁸F-FLT Is Unlikely to Cause Significant Hepatorenal or Hematologic Toxicity. Journal of Nuclear Medicine, 2010, 51, 824.2-825.	5.0	1
161	Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts. Cancer Research, 2010, 70, 4292-4296.	0.9	12
162	Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. Journal of Nuclear Medicine, 2010, 51, 401-412.	5.0	95

#	Article	IF	Citations
163	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood, 2010, 116, 1498-1505.	1.4	196
164	Clinical Value of 18-Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma. Thyroid, 2010, 20, 527-533.	4.5	78
165	Cost-Effectiveness of Hybrid PET/CT for Staging of Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2010, 51, 1668-1675.	5.0	62
166	Alternative PET Tracers in Musculoskeletal Disease. PET Clinics, 2010, 5, 363-374.	3.0	3
167	Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches. Journal of Nuclear Medicine Technology, 2010, 38, 6-17.	0.8	81
168	[18F]FLT Is Superior to [18F]FDG to Early Predict Response to Specific Inhibitors of NPM-ALK-Dependent Pathways In a Human ALCL Xenograft Model. Blood, 2010, 116, 2849-2849.	1.4	0
169	Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. Journal of Oncology, 2009, 2009, 1-13.	1.3	118
170	Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker ¹⁸F-Fluorothymidine. Journal of Nuclear Medicine, 2009, 50, 1441-1447.	5.0	49
171	Reply: SPECT/CT. Journal of Nuclear Medicine, 2009, 50, 1009.2-1010.	5.0	2
172	Clinical Value and Limitations of [11C]-Methionine PET for Detection and Localization of Suspected Parathyroid Adenomas. Molecular Imaging and Biology, 2009, 11, 356-363.	2.6	36
173	[11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World Journal of Urology, 2009, 27, 619-625.	2.2	89
174	Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 48-52.	6.4	146
175	Demonstration of metastatic tumour growth following vessel structures by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1021-1021.	6.4	1
176	Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1807-1812.	6.4	419
177	Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine. Methods, 2009, 48, 205-215.	3.8	49
178	Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions -Results from a Large Prospective Clinical Trial. Molecular Imaging and Biology, 2008, 10, 121-128.	2.6	13
179	Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment. Molecular Imaging and Biology, 2008, 10, 349-355.	2.6	42
180	Chromosome instability and tumor lethality suppression in carcinogenesis. Journal of Cellular Biochemistry, 2008, 105, 1327-1341.	2.6	3

#	Article	IF	Citations
181	Use of integrated FDG-PET/CT in sarcoidosis. Clinical Imaging, 2008, 32, 269-273.	1.5	27
182	First Demonstration of Leukemia Imaging with the Proliferation Marker ¹⁸F-Fluorodeoxythymidine. Journal of Nuclear Medicine, 2008, 49, 1756-1762.	5.0	68
183	Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: A 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. NeuroImage, 2008, 41, 718-727.	4.2	73
184	Short Communication: ¹⁸F-Immuno-PET: Determination of Anti-CD66 Biodistribution in a Patient with High-Risk Leukemia. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 819-824.	1.0	14
185	SPECT/CT. Journal of Nuclear Medicine, 2008, 49, 1305-1319.	5.0	280
186	Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine. Clinical Cancer Research, 2008, 14, 2970-2977.	7.0	69
187	Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. Clinical Cancer Research, 2008, 14, 2012-2018.	7.0	140
188	In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors. Journal of Nuclear Medicine, 2008, 49, 1437-1444.	5.0	42
189	Navigated nuclear probes for intra-operative functional imaging. , 2008, , .		2
190	PET Imaging of Breast Cancer Molecular Biomarkers. , 2008, , 145-156.		0
191	Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 2007, 25, 571-578.	1.6	1,275
192	Early Response Assessment Using 3â€²-Deoxy-3â€²-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 3552-3558.	7.0	151
193	Synthesis and biodistribution of 3â€²-fluoro-5-[131I]iodo-2â€²-deoxyuridine: a comparative study of [131I]FLIdU and [18F]FLT. Nuclear Medicine and Biology, 2007, 34, 273-281.	0.6	1
194	123I-ITdU-Mediated Nanoirradiation of DNA Efficiently Induces Cell Kill in HL60 Leukemia Cells and in Doxorubicin-, Â-, or Â-Radiation-Resistant Cell Lines. Journal of Nuclear Medicine, 2007, 48, 1000-1007.	5.0	25
195	Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis. Journal of Nuclear Medicine, 2007, 48, 1945-1950.	5.0	113
196	Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1355-1364.	6.4	53
197	Positron detection for the intraoperative localisation of cancer deposits. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1534-1544.	6.4	60
198	Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1775-1782.	6.4	62

#	Article	IF	Citations
199	Assessment of disease activity in alveolar echinococcosis: a comparison of contrast-enhanced ultrasound, three-phase helical CT and [18F]fluorodeoxyglucose positron-emission tomography. Abdominal Imaging, 2007, 32, 730-736.	2.0	68
200	Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [18F] fluorodeoxyglucose positron emission tomography. Abdominal Imaging, 2007, 32, 730.	2.0	4
201	Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. Nuklearmedizin - NuclearMedicine, 2007, 46, 239-43.	0.7	11
202	Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of-amyloid plaques. Nuklearmedizin - NuclearMedicine, 2007, , .	0.7	1
203	Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. Nuclear Medicine and Biology, 2006, 33, 359-366.	0.6	19
204	Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. Journal of Internal Medicine, 2006, 260, 545-550.	6.0	67
205	Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Research, 2006, 66, 11055-11061.	0.9	173
206	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British Journal of Haematology, 2005, 130, 604-613.	2.5	92
207	Clinical relevance of imaging proliferative activity in lung nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 525-533.	6.4	101
208	Internal radionuclide therapy: The ULMDOS software for treatment planning. Medical Physics, 2005, 32, 2399-2405.	3.0	36
209	Lymph Node Staging in Lung Cancer Using [18F]FDG-PET. Thoracic and Cardiovascular Surgeon, 2004, 52, 96-101.	1.0	35
210	Prospective Evaluation of Factors Influencing Success Rates of Sentinel Node Biopsy in 814 Breast Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 784-790.	1.0	19
211	[18 F] 3-deoxy-3â€²-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18 f]-fluoro-2-deoxy- d -glucose positron emission tomography in the workup of suspicious central focal lesions?. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 1093-1099.	0.8	33
212	Biological characterisation of breast cancer by means of PET. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S80-S87.	6.4	90
213	Structured treatment interruption in patients with alveolar echinococcosis. Hepatology, 2004, 39, 509-517.	7.3	153
214	F-18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost-Effectiveness, and Impact on Patient Management. Journal of Bone and Mineral Research, 2003, 18, 2206-2214.	2.8	155
215	Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Therapy, 2003, 10, 403-410.	4.6	39
216	Gene silencing by adenovirusâ€delivered siRNA. FEBS Letters, 2003, 539, 111-114.	2.8	176

#	Article	IF	Citations
217	Salvage Treatment with Amphotericin B in Progressive Human Alveolar Echinococcosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 3586-3591.	3.2	58
218	Positron Emission Tomography (PET) for Staging of Solitary Plasmacytoma. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 841-845.	1.0	110
219	Staging of Nonâ€“Small-Cell Lung Cancer with Integrated PET and CT. New England Journal of Medicine, 2003, 349, 1188-1190.	27.0	3
220	3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Research, 2003, 63, 2681-7.	0.9	128
221	Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. Journal of Nuclear Medicine, 2003, 44, 1426-31.	5.0	281
222	Myeloablative Radioimmunotherapy with Re-188-anti-CD66-Antibody for Conditioning of High-Risk Leukemia Patients Prior to Stem Cell Transplantation: Biodistribution, Biokinetics and Immediate Toxicities. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 151-163.	1.0	38
223	FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1317-1323.	6.4	274
224	3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Research, 2002, 62, 3331-4.	0.9	162
225	Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 807-815.	2.1	36
226	Elevated FDG Uptake in the Lactating Human Breast. Clinical Nuclear Medicine, 2001, 26, 577-578.	1.3	3
227	Rhenium 188â€“labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood, 2001, 98, 565-572.	1.4	166
228	The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget, 0, 7, 41233-41241.	1.8	16
229	CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. Leukemia and Lymphoma, 0, , 1-10.	1.3	0